Walder Wyss advises Swisscanto Invest on Series B financing round of Memo Therapeutics

Walder Wyss has advised Swisscanto Invest in connection with its investment as lead investor in a CHF 14 mio. Series B Financing Round of Memo Therapeutics, an innovator in the field of antibody discovery and immune repertoire analysis. Proceeds from the financing round will be primarily used to advance development of MTX-COVAB, Memo Therapeutics’ lead antibody candidate for the treatment of Covid-19, through to Phase II clinical studies.

The team

The Walder Wyss team has been led by Alex Nikitine (Partner, Corporate/M&A – pictured) and included Thiemo Sturny (Partner, Corporate/M&A), Dimitrios Berger (Associate, Corporate/M&A), Hugh Reeves (Senior Associate, IP/IT) and Judith Rothen (Trainee, Corporate/M&A).

Walder Wyss advises Swisscanto Invest on Series B financing round of Memo Therapeutics

FabioAdmin

Legalcommunity.ch

Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2022 © All rights Reserved. Design by Origami Creative Studio

SHARE

Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram